Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
Background/Aims: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671)....
Main Authors: | Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of Intestinal Diseases
2017-07-01
|
Series: | Intestinal Research |
Subjects: | |
Online Access: | https://doi.org/10.5217/ir.2017.15.3.395 |
Similar Items
-
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
by: Yasuo Suzuki, et al.
Published: (2021-07-01) -
Clinical heterogeneity of ocular Behçet’s syndrome versus intestinal Behçet’s syndrome: a cross-sectional study from Shanghai Behçet’s syndrome database
by: Cheng-cheng Hou, et al.
Published: (2022-04-01) -
Are mucocutaneous lesions seasonal in Behçet's disease?
by: Bilge Fettahlıoğlu Karaman
Published: (2022-03-01) -
Pulmonary Sarcoidosis in Behçet's Disease Treated with Adalimumab
by: Marlene Louro, et al.
Published: (2017-05-01) -
Amyloidosis with recurrent oral and peptic ulcers mimicking Behcet's syndrome: A case report
by: Jiajing Peng, et al.
Published: (2022-03-01)